Back to Journals » Lung Cancer: Targets and Therapy » Volume 10

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Authors Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET

Received 17 October 2018

Accepted for publication 11 January 2019

Published 8 February 2019 Volume 2019:10 Pages 11—20


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Sai-Hong Ignatius Ou

Stephanie M Barrows,1 Kelly Wright,1 Catherine Copley-Merriman,1 James A Kaye,2 Marc Chioda,3 Robin Wiltshire,4 Knut Martin Torgersen,5 Elizabeth T Masters6

1Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; 2Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA; 3Medical Affairs, Pfizer, Inc., New York, NY, USA; 4Medical Affairs, Pfizer Limited, Walton Oaks, UK; 5Medical Affairs, Pfizer, Inc., Oslo, Norway; 6Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA

Abstract: The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4–89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5–22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.

Keywords: ALK, non-small-cell lung cancer, NSCLC, carcinoma, non-small-cell lung

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]